NAFLD Opportunity ENDRA’s TAEUS platform targets quantifying liver fat to detect and monitor NAFLD, addressing a large and growing market with high cost and invasiveness of current MRI and biopsy methods.

Biomarker potential Strategic direction to deploy TAEUS as a biomarker solution for metabolic diseases in patients treated with GLP-1 therapies and MASH conditions creates cross-selling opportunities with pharma and clinics focused on metabolic health.

Geographic expansion Recent openings in New York, San Francisco, and London indicate capacity to accelerate development and widen sales channels, enabling regional pilots and early adopter deployments.

Funding and momentum Past fundraising activity and public offerings suggest ongoing capital readiness to support regulatory activities, clinical validation, and market entry efforts—a favorable signal for sales planning and long-cycle deals.

Tech stack readiness Leverages cloud, analytics, and modern development tools (AWS, Google Ads, GitHub, Docker, Firebase) that can support scalable deployment, partner integrations, and data-driven outcomes to attract hospital and clinic customers.